Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Metadata
Title
Differential expression of Runx2 and Indian hedgehog in cartilaginous tumors
Authors
Hye-Rim Park
Yong-Koo Park
Publication date
01-03-2007
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2007
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/BF02893438

Other articles of this Issue 1/2007

Pathology & Oncology Research 1/2007 Go to the issue

Article

Prevalence of SLC22A4 1672T and SLC22A5 −207C combination defined TC haplotype in Hungarian ulcerative colitis patients

Article

Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma

Article

Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease

Article

Clinicopathological significance and linkage of the distribution of HIF-1α and GLUT-1 in human primary colorectal cancer

Case Report

Follicular lymphoma with prominent sclerosis (“sclerosing variant of follicular lymphoma”) exhibiting a mesenteric bulky mass resembling inflammatory pseudotumor. Report of three cases

Article

Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits